0JDK Stock Overview
Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Iovance Biotherapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$11.37 |
| 52 Week High | US$18.31 |
| 52 Week Low | US$3.22 |
| Beta | 0.59 |
| 1 Month Change | -24.23% |
| 3 Month Change | 47.85% |
| 1 Year Change | 108.43% |
| 3 Year Change | -65.39% |
| 5 Year Change | -0.26% |
| Change since IPO | -17.01% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0JDK | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -5.6% | -1.9% | -0.9% |
| 1Y | 108.4% | -30.5% | -1.8% |
Return vs Industry: 0JDK exceeded the UK Biotechs industry which returned -30.5% over the past year.
Return vs Market: 0JDK exceeded the UK Market which returned -1.8% over the past year.
Price Volatility
| 0JDK volatility | |
|---|---|
| 0JDK Average Weekly Movement | 13.9% |
| Biotechs Industry Average Movement | 7.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0JDK's share price has been volatile over the past 3 months.
Volatility Over Time: 0JDK's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 557 | Frederick Vogt | www.iovance.com |
Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers.
Iovance Biotherapeutics, Inc. Fundamentals Summary
| 0JDK fundamental statistics | |
|---|---|
| Market cap | US$3.16b |
| Earnings (TTM) | -US$444.04m |
| Revenue (TTM) | US$1.19m |
2,659x
P/S Ratio-7.1x
P/E RatioIs 0JDK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0JDK income statement (TTM) | |
|---|---|
| Revenue | US$1.19m |
| Cost of Revenue | US$10.76m |
| Gross Profit | -US$9.57m |
| Other Expenses | US$434.47m |
| Earnings | -US$444.04m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.59 |
| Gross Margin | -804.54% |
| Net Profit Margin | -37,345.42% |
| Debt/Equity Ratio | 0.2% |
How did 0JDK perform over the long term?
See historical performance and comparison